$IMAX

IMAX (NYSE: IMAX) officer to sell 100K shares after recent August trades

IMAX Corporation officer Richard Gelfond plans to sell 100,000 shares, valued at $5.27M, under Rule 144 via Goldman Sachs. Gelfond sold 356,757 shares in August 2026, totaling $18.66M. IMAX has 54.84M shares outstanding as of August 20, 2026.

Original reporting
Published Aug 20, 2026, 10:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 6:50 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$IMAX
Bearish
high confidence
Mentioned
$IMAX
Relevance
6/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$IMAXBearishMed
01

Why it matters

The filing introduces a new supply factor that could depress the stock price if the market perceives it as a lack of confidence.

02

Market read

Primary insider sale disclosure; relevant for short‑term traders monitoring supply dynamics.

03

What to watch

Recent strong earnings or upcoming product announcements could offset the supply pressure.

Relevance 6/10Novelty 6/10Timing: today

Background

Form 144 filings disclose planned insider sales, providing transparency on potential new share supply.

Company-level read

Ticker impact

$IMAXBearishHigh confidence
Context

Officer Richard Gelfond filed a Form 144 to sell up to 100,000 IMAX shares worth $5.27 million, indicating new insider supply.

Expected impact

Modest downside pressure over the next few days as the market absorbs the potential share release.

Evidence & confidence

Form 144 filings are primary disclosures; the size ($5.27 M) is material for a mid‑cap and can influence sentiment.

Market effects

Potentially signals increased insider activity in the entertainment/technology sector, but limited broader impact.

U.S. market focus; no notable regional effect.

Limited to IMAX investors; unlikely to affect global markets.

Counterpoint

The sale may be a routine liquidity move and not reflect negative fundamentals; price could remain stable.

Key entities

  • Richard Gelfond

    IMAX officer filing the Form 144 to sell shares.

  • Goldman Sachs & Co. LLC

    Designated broker for the share sale.

Related articles

$IMAXMed

Why IMAX Stock Climbed to a New All-Time High Today

IMAX stock reached a new all-time high on Monday, rising 3.89% to $54.79. The surge was driven by the record-breaking success of The Odyssey, which became the highest-grossing IMAX release. CEO Rich Gelfond expects this to be their best year. Analyst Steve Frankel predicts IMAX will exceed estimates in the second half of 2026, with shares potentially rising to $60. The company's Q2 2026 revenue grew 12% to $103 million, with adjusted earnings up 65% to $0.43 per share.

$IMAXMed

“The Odyssey” Demand Drives IMAX Shares Higher

IMAX reported Q2 2026 revenue of $103M (up 12% YoY) and EPS of $0.43 (up 65%), driven by strong demand for 'The Odyssey'. The stock has gained 42% YTD, with institutional inflows contributing to a 103.5% rise over the past year. IMAX shows strong sales and EPS growth rates of 11.7% and 18.7% respectively over three years, with EPS expected to rise 14% this year.

$IMAXMed

Why IMAX Stock Rallied on Monday

IMAX shares rose about 5% on Monday after the company said Christopher Nolan’s film The Odyssey became the highest-grossing IMAX release of all time. IMAX reported $289 million in ticket sales, plus $37 million in the fourth weekend, and said IMAX theaters account for 26% of total tickets. IMAX added that 70mm locations have grossed over $37 million and presales near $40 million.

$IMAXMed

Why IMAX Stock Soared on Monday

IMAX said The Odyssey helped it post its highest-ever monthly box-office results, with July box-office revenue of $257 million, up 47% from the prior record. Ticket sales for The Odyssey totaled $221 million. IMAX also announced an upcoming run for Spider-Man: Brand New Day and shares closed Monday nearly 7% higher.

$IMAXMed

'The Odyssey' fuels Imax stock to all-time high. CEO calls momentum a 'flywheel'

Imax shares hit an all-time high Monday, up nearly 6%, after box office momentum from Christopher Nolan’s “The Odyssey.” The company said the film is tracking almost double “Oppenheimer” (2023) and generated $221 million globally, about 25% of Universal’s total. CEO Rich Gelfond attributed results to a “flywheel” of theater expansion and recurring cash flow.